Jim Birchenough
Stock Analyst at Wells Fargo
(2.92)
# 1,997
Out of 4,829 analysts
41
Total ratings
66.67%
Success rate
27.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.75 | +167.81% | 2 | Dec 31, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $7.87 | -61.88% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $37.59 | +86.22% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.09 | +1,813.88% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $12.02 | +299.33% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.30 | +2,271.27% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.07 | +12,049.53% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.37 | +921.90% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $25.70 | +464.20% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $103.82 | -39.32% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $29.33 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $13.15 | +325.86% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $575.63 | +27.51% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.23 | +4,155.32% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.84 | +382.46% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.75
Upside: +167.81%
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $7.87
Upside: -61.88%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $37.59
Upside: +86.22%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.09
Upside: +1,813.88%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $12.02
Upside: +299.33%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.30
Upside: +2,271.27%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.07
Upside: +12,049.53%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.37
Upside: +921.90%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $25.70
Upside: +464.20%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $103.82
Upside: -39.32%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $29.33
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $13.15
Upside: +325.86%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $575.63
Upside: +27.51%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.23
Upside: +4,155.32%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.84
Upside: +382.46%